So, here's the latest in the weight-loss drug wars: Eli Lilly and Co. (LLY) just launched its new obesity pill, and the early numbers are in. According to IQVIA data cited by Reuters, it logged 1,390 prescriptions in the U.S. for the week ended April 10. That's not bad for a debut, but when you stack it up against Novo Nordisk A/S's (NVO) oral Wegovy, which saw 3,071 prescriptions in just its first four days back in January, it looks like a measured start. Investors are tracking this closely because, well, the competition in this space is getting intense, and everyone wants to know who's winning the race to replace those injectables with something you can swallow.

Early Prescription Trends Show Slower Start For Lilly

Let's break down those numbers. Lilly's pill hit 1,390 scripts in its first full week. Novo's oral Wegovy, on the other hand, managed over 3,000 in less than half that time. The data highlights a slower early ramp for Lilly, though to be fair, the company had warned that early prescription trends might be a bit variable. It's like showing up to a party fashionably late—sometimes it works, sometimes you miss the best snacks. In this case, Novo seems to have grabbed the appetizers.

Novo Maintains Lead In Weekly Prescription Volume

And Novo isn't just resting on its laurels. That same IQVIA data shows oral Wegovy was prescribed 113,354 times during the week ended April 10, up from 105,366 the week before. So, it's not only holding its ground but growing steadily. Think of it as the seasoned player who's already figured out the game while the new kid is still learning the rules. For Lilly, catching up will mean more than just a strong launch—it'll need to build momentum in a market that's already moving fast.

Market Competition Intensifies As Oral Segment Evolves

Why does this matter? Because the obesity drug market has been dominated by injectables for a while, but oral alternatives are emerging as the next big battleground. Investors are watching these prescription trends like hawks as Lilly and its Danish rival duke it out. It's not just about who has the better pill; it's about how these companies are pivoting toward cash-pay consumer models, making weight-loss drugs more accessible without always going through insurance. The data offers early insight into how these pills are performing, and so far, Novo has the edge.

Launch Timing And Distribution Channels Influence Uptake

Timing and distribution play a big role here. Lilly's obesity pill was approved on April 1 and started accepting prescriptions immediately via LillyDirect, its direct-to-consumer platform. Shipments kicked off on April 6, with broader availability across U.S. retail pharmacies and telehealth platforms rolling out from April 9. So, it's a phased launch—kind of like a soft opening before the grand premiere.

Meanwhile, Novo has been busy too. In March, they introduced a multi-month subscription program for Wegovy, aiming to make pricing more predictable for self-pay patients and improve long-term adherence. And earlier that month, the FDA approved a higher-dose version of Wegovy, expanding its treatment portfolio for adults with obesity. It's all part of a strategy to lock in patients and stay ahead in the game.

As for the stock market, Eli Lilly shares were up 2.76% at $929.01 at the time of publication on Friday, according to market data. So, investors aren't panicking over the slower start—they might be betting on the long game. After all, in the world of weight-loss drugs, it's not just about the first week; it's about who can keep the momentum going as the oral segment evolves.